FindTrial
Sign In

COMPARISON OF RAMIPRIL AND SACUBITRIL-VALSARTAN IN PATIENTS WITH MYOCARDIAL INFARCTION [HEART ATTACK] WITH DECREASED HEART FUNCTION

COMPARATIVE STUDY OF RAMIPRIL AND SACUBITRIL-VALSARTAN IN POST ACUTE CORONARY SYNDROME PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION - A RANDOMISED CONTROLLED TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037441
Enrollment
60
Registered
2021-10-21
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I219- Acute myocardial infarction, unspecified

Interventions

Intervention1: SACUBITRIL-VALSARTAN IN POST ACS PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION: Sacubitril-Valsartan will be started at a dose of 12/13 mg BID in patients with SBP between 100-140

Sponsors

Dr Rajendra Prasad Government Medical College Kangra at Tanda Himachal Pradesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to give consent. 2.All patients of age 18 years or more of both genders will be recruited in the study. 3.Post-ACS patients who have LVEF 4.Patient must be treated with aspirin, clopidogrel, statins and beta blocker as per guidelines

Exclusion criteria

Exclusion criteria: 1.Patients refusing to give consent. 2.History of angioedema, 3.An eGFR 4.Serum potassium >5.2 mmol/L, 5.Symptomatic hypotension or a SBP 6.Were in the midst of a heart failure exacerbation. 7.Post MI patients with LVEF >40% 8.Pregnant females or lactating mothers 9.Known contraindications to study drugs 10.Peripartum Cardiomyopathy (PPCMP)/ Combination Chemotherapy (CCT) induced CMP 11.H/O severe pulmonary disease, TIA or Stroke 12.Acute decompensated heart failure 13.Presence of any disease with life expectancy less than 5 years 14.Presence of heart disease with aortic or mitral valve disease except mitral regurgitation 15.Symptomatic bradycardia without pacemaker

Design outcomes

Primary

MeasureTime frame
Primary objective of the study is to test that sacubitril-valsartan is non-inferior to ramipril in composite end points i.e. Major Adverse Cardiovascular Events (MACE) in patients with ACS at short term (1 month) and intermediate term (6 month).Timepoint: 1st week 2nd week 4th-6th week 6th-8th week 4th month 6th month—

Secondary

MeasureTime frame
Improvement in NYHA FC All cause mortality Change in biomarkers ( BNP, Trop T, CRP ) Timepoint: 1 month, 6 month—

Countries

India

Contacts

Public ContactDr Dinesh Kansal

Dr Rajendra Prasad Government Medical College Kangra at Tanda

dr.gaurav.sharma1511986@gmail.com7831839310

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026